BriaCell Therapeutics Corp (NASDAQ: BCTX) is a clinical-stage biotechnology company developing immunotherapy treatments for advanced breast cancer. The company generates no product revenue and self-describes as a pre-revenue clinical stage company in its 10-K filed October 16, 2025. BriaCell's primary program is Bria-IMT, a whole-cell cancer immunotherapy candidate being evaluated in patients with advanced metastatic breast cancer who have failed at least two prior lines of therapy. The FDA has granted Fast Track status to the Bria-IMT combination regimen. A pivotal Phase 3 study is underway, designed to enroll 177 patients in the Bria-IMT combination arm versus 177 patients receiving physician's choice of treatment, with overall survival as the primary endpoint. BriaCell holds a 63.1% interest in BC Therapeutics as of the fiscal year ended July 31, 2025. The company is incorporated in Canada and files with the SEC. Operations are funded through equity issuances, including multiple warrant and placement agent warrant transactions executed between September 2024 and July 2025.

Revenue model

No product revenue. BriaCell is a pre-revenue company funded by equity capital raises, including multiple common stock and warrant offerings executed during fiscal year ended July 31, 2025. Research costs include salaries, clinical trial expenses, and investigational drug manufacturing costs.

Products and services

Bria-IMT: a whole-cell cancer immunotherapy candidate for advanced metastatic breast cancer, currently in a pivotal Phase 3 clinical trial with FDA Fast Track designation. The Phase 3 study primary endpoint is overall survival; a Biologics License Application (BLA) submission is planned upon successful completion.

Customers and end markets

Target patient population is advanced metastatic breast cancer patients who have failed at least two prior lines of therapy, an area with no approved therapy as of the 10-K filing date. End market is oncology, specifically breast cancer treatment.

Value-chain role

Clinical-stage drug developer. BriaCell conducts research and development and clinical trials internally and through partners, including a service agreement with UC Davis. The company has not yet reached commercialization.

Geographic exposure

Incorporated in Canada. Operates under both Canadian and U.S. regulatory frameworks, including FDA oversight. Files reports with the SEC under Section 12(b) of the Exchange Act.

Source: SEC 10-K, filed 2025-10-16

Industry: Pharmaceutical Preparations Peers: Alpha Compute Corp ESSA Pharma Inc. Fusion Pharmaceuticals Inc. Repare Therapeutics Inc. Xenon Pharmaceuticals Inc Zymeworks BC Inc.